Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2024 at "Hematological Oncology"
DOI: 10.1002/hon.70017
Abstract: Polatuzumab vedotin plus R‐CHP (Pola‐R‐CHP) is approved as a new standard first‐line therapy for diffuse large B‐cell lymphoma (DLBCL) based on the POLARIX trial. However, real‐world data on its efficacy and safety in unselected patients… read more here.
Keywords: study; real world; chp; polatuzumab vedotin ... See more keywords
Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Open"
DOI: 10.1136/bmjopen-2024-086251
Abstract: Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China. Design A Markov model was constructed to analyse the cost-effectiveness… read more here.
Keywords: cost; pola chp; cost effectiveness; previously untreated ... See more keywords
Abstract 4147489: POLA-R-CHP: Promising Results in DLBCL with Cardiac Involvement
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4147489
Abstract: Polatuzumab Vedotin is a novel antibody-drug conjugate that targets CD79b, a B-cell antigen receptor expressed in mature B-cell lymphomas such as Diffuse Large B-Cell Lymphoma (DLBCL) 1 . Yet, its effect on cardiac disease is… read more here.
Keywords: oncology; dlbcl cardiac; cardiac involvement; cell ... See more keywords
Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200395
Abstract: Background: Epcor, a subcutaneous CD3xCD20 bispecific antibody, is approved as monotherapy for adults with relapsed or refractory DLBCL after ≥2 lines of systemic therapy. Combining epcor with antineoplastic agents that have complementary mechanisms of action… read more here.
Keywords: treatment; pola; mrd negativity; epcor ... See more keywords
Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200404
Abstract: Background The POLARIX trial reported the progression-free survival superiority of Pola-R-CHP [polatuzumab vedotin (Pola), rituximab, cyclophosphamide (CPA), doxorubicin (DXR), and prednisolone] as compared with that of R-CHOP (rituximab, CPA, DXR, vincristine, and prednisolone) in previously… read more here.
Keywords: pts years; age; pola chp; years age ... See more keywords
Pola-R-CHP Regimen Exhibited a High Response Rate and Good Treatment Tolerability for Newly Diagnosed Double-Expressor Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200746
Abstract: Background: Double-expressor lymphoma (DEL) is characterized by the overexpression of C-MYC and BCL2 proteins without underlying chromosomal rearrangements. Although it is not classified as a distinct entity in the current World Health Organization classification, DEL… read more here.
Keywords: chp regimen; newly diagnosed; response rate; lymphoma ... See more keywords
Safety Profile of Infectious Events for First-Line Pola-R-CHP Therapy in Elderly Patients with Diffuse Large B-Cell Lymphoma Including Those 80+ Years Old in Japan
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-203198
Abstract: Background and objectives Safety data in elderly patients (pts) aged 80+ with diffuse large B-cell lymphoma (DLBCL) treated with Pola-R-CHP are limited. This study aims to describe the incidence of infectious adverse events and related… read more here.
Keywords: chp group; pola chp; chop group; group ... See more keywords
Circulating Tumour DNA Measurements As an Early Prognostic Indicator for Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Pola-R-CHP Regimen
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206716
Abstract: Objective The POLARIX trial showed that pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) significantly improved 2-year event-free survival (EFS) and progression-free survival (PFS) compared with R-CHOP in DLBCL patients with intermediate- and high-risk. However,… read more here.
Keywords: chp regimen; circulating tumour; treated pola; dlbcl patients ... See more keywords
CD5 positivity and aberrant P53 expression predict primary refractoriness to first-line pola-R-CHP in patients with diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1887
Abstract: Background: The Pola-R-CHP regimen has emerged as an effective initial treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Nevertheless, a subset of patients demonstrates suboptimal responses. Identifying risk factors for primary refractoriness… read more here.
Keywords: treatment; cd5 positivity; pola; aberrant p53 ... See more keywords
Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1916
Abstract: Background and Aim: CD5-positive diffuse large B-cell lymphoma (DLBCL) represents an aggressive subtype with particularly poor clinical outcomes. Following China's approval of Pola-R-CHP (polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone) for first-line DLBCL… read more here.
Keywords: pola chp; treatment; dlbcl; positive dlbcl ... See more keywords
Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3698
Abstract: Dual-expressor DLBCL (DEL), characterized by MYC/BCL2 co-expression (20-30% of cases), demonstrates inferior outcomes with R-CHOP (3-year PFS 30-40%). The POLARIX trial established pola-R-CHP superiority in high-risk DLBCL, with DEL subgroups showing improved 2-year PFS (64.2%… read more here.
Keywords: treatment; dlbcl; pola; risk ... See more keywords